



PRESS RELEASE

Contacts

Punnie Donohue

ConvaTec
908-904-2151
punnie.donohue@convatec.com

Nicole Elovitz

HemCon Medical Technologies, Inc.
971-223-4918
nicolee@hemcon.com

CONVATEC AND HEMCON ANNOUNCE CO-PROMOTION AGREEMENT

Medical Innovators Partner to Bring Advanced Wound and Critical Care Products to U.S. Armed Forces

SKILLMAN, NJ (April 15, 2009) — ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today it has signed a co-promotion agreement with HemCon Medical Technologies Inc. to market ConvaTec advanced wound and critical care products to the U.S. Armed Forces.

Through the agreement, HemCon, a leading global developer of advanced medical products, is granted sales and marketing rights to leading ConvaTec products, the company's AQUACEL[®] and AQUACEL[®] Ag dressings for managing acute and chronic wounds and its Flexi-Seal[®] Fecal Management System (FMS) for the management of fecal incontinence.

AQUACEL[®] and AQUACEL[®] Ag dressings feature the unique benefits of Hydrofiber[®] Technology. These dressings gel on contact with wound fluid to provide a moist wound healing environment, manage exudate, protect the periwound skin¹ and reduce pain in situ and on removal.^{2,3,4} In addition, AQUACEL[®] Ag dressing provides the broad-spectrum antimicrobial properties of ionic silver, which kills a broad range of pathogens in the dressing, including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE) as demonstrated in vitro.⁵

The innovative Flexi-Seal[®] FMS, a temporary containment device for patients with acute fecal incontinence, was designed to safely and effectively divert fecal matter, protect patients' wounds from fecal contamination, and reduce the risk of both skin breakdown and spread of infection, such as *Clostridium difficile* (*C. difficile*).

"ConvaTec is proud to be partnering with HemCon to bring our advanced wound and critical care products to the U.S. Armed Forces," commented Michael Steadman, President, Wound Therapeutics and ConvaTec USA. "We hope this agreement also will form the basis of similar initiatives to expand our presence in specialized, acute care settings."

"This new arrangement with ConvaTec will provide the U.S. Armed Forces with the support and products they need to enable safer, more stable recoveries," said Bill Block, President, HemCon U.S. "As a trusted, proven Military partner, HemCon continues to pioneer and deliver new products for wound care and healing that bring innovative solutions to the Military and deliver medical technologies when and where they are needed most."



Our world is what we make of it™



About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions – Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices – ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skillman, New Jersey, the company oversees more than 8,000 employees in over 90 countries serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.

About HemCon Medical Technologies

HemCon Medical Technologies Inc. is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including Lyophilized Human Plasma and Nanospider™ technologies. HemCon is headquartered in Portland, OR, with additional commercial operations in Ireland; England; Germany and the Czech Republic. For more information, please visit www.hemcon.com.

###

References

1. Robinson BJ. The use of a Hydrofiber® dressing in wound management. *J Wound Care* 2000;9(1):32-34.
2. Armstrong SH, Brown DA, Hill E, Ruckley CV. A randomized trial of a new Hydrofiber® dressing, AQUACEL®, and an alginate in the treatment of exuding leg ulcers. Presented at: 5th European Conference on Advances in Wound Management; Harrogate, UK: November 1995.
3. Caruso DM, Foster KN, Blome-Eberwein SA et al. Randomized clinical study of Hydrofiber® dressing with silver or silver sulfadiazine in the management of partial-thickness burns. *J Burn Care Res.* 2006; 27(3):298-309.
4. Kogan L, Moldavsky M, Szvalb S, Govrin-Yehudain J. Comparative study of Aquacel® and Silverol® treatment in burns. *Ann Burns Fire Disasters.* 2004; 17(4):201-207.
5. Jones SA, Bowler PG, Walker M, Parsons D. Controlling wound bioburden with a novel silver-containing Hydrofiber® dressing. *Wound Repair Regen.* 2004;12(3):288-294.

AQUACEL, Hydrofiber, and FlexiSeal are registered trademarks of ConvaTec Inc.

Our world is what we make of it is a trademark of ConvaTec Inc.

© 2009 ConvaTec Inc.

AP-007329-US



Our world is what we make of it™